First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

Autor: Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Lipson EJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD., Hodi FS; Dana-Farber Cancer Institute, Boston, MA., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Larkin J; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Lao C; University of Michigan, Ann Arbor, MI., Grob JJ; Aix-Marseille University, Hôpital de la Timone, Marseille, France., Ejzykowicz F; Bristol Myers Squibb, Princeton, NJ., Moshyk A; Bristol Myers Squibb, Princeton, NJ., Garcia-Horton V; Analysis Group, Inc, Boston, MA., Zhou ZY; Analysis Group, Inc, Boston, MA., Xin Y; Analysis Group, Inc, Boston, MA., Palaia J; Bristol Myers Squibb, Princeton, NJ., McDonald L; Bristol Myers Squibb, Princeton, NJ., Keidel S; Bristol Myers Squibb, Princeton, NJ., Salvatore A; Bristol Myers Squibb, Princeton, NJ., Patel D; Bristol Myers Squibb, Princeton, NJ., Sakkal LA; Bristol Myers Squibb, Princeton, NJ., Tawbi H; The University of Texas MD Anderson Cancer Center, Houston, TX., Schadendorf D; University of Essen and the German Cancer Consortium, Partner Site, Essen, Germany.; National Center for Tumor Diseases (NCT-West), Campus Essen, Essen, Germany.; University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Nov 20; Vol. 42 (33), pp. 3926-3934. Date of Electronic Publication: 2024 Aug 13.

Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma.

Autor: Cella D; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Suarez C; Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Blum SI; Bristol Myers Squibb, Princeton, NJ, USA., Ejzykowicz F; Bristol Myers Squibb, Princeton, NJ, USA., Hamilton M; Bristol Myers Squibb, Princeton, NJ, USA., Wallace JF; Exelixis, Alameda, CA, USA., Simsek B; Bristol Myers Squibb, Princeton, NJ, USA., Zhang J; Bristol Myers Squibb, Princeton, NJ, USA., Ivanescu C; IQVIA, Amsterdam, Netherlands., Choueiri TK; The Lank Center for Genitourinary Oncology, Boston, MA, USA., Apolo AB; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Publikováno v: Future oncology (London, England) [Future Oncol] 2024 Oct 25, pp. 1-14. Date of Electronic Publication: 2024 Oct 25.

CO153 Predicting Overall Survival (OS) Benefit in Previously Untreated Metastatic Melanoma From Improvements in Response Outcomes: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)

Autor: Leung, L., Serafini, P., Srinivasan, S., Ejzykowicz, F., Pourrahmat, MM., Moshyk, A., Kurt, M.

Publikováno v: In Value in Health June 2024 27(6) Supplement:S46-S46

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.

Autor: McGregor B; The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile., Suárez C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Bourlon MT; Hematology-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Barata PC; Deming Department of Medicine, Tulane Medical School, New Orleans, LA, USA., Gulati S; Division of Hematology and Oncology, Department of Medicine, University of Cincinnati Cancer Center, Cincinnati, OH, USA., Huo S; Worldwide Health Economics and Outcomes Research US Market, Bristol Myers Squibb, Princeton, NJ, USA., Ejzykowicz F; Worldwide Health Economics and Outcomes Research US Market, Bristol Myers Squibb, Princeton, NJ, USA., Blum SI; Worldwide Health Economics and Outcomes Research US Market, Bristol Myers Squibb, Princeton, NJ, USA., Del Tejo V; US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA., Hamilton M; Worldwide Health Economics and Outcomes Research US Market, Bristol Myers Squibb, Princeton, NJ, USA., May JR; Worldwide Health Economics and Outcomes Research Markets, Bristol Myers Squibb, Uxbridge, UK., Du EX; Analysis Group, Inc., Los Angeles, CA, USA., Wu A; Analysis Group, Inc., Los Angeles, CA, USA., Kral P; Patient Centered Solutions, IQVIA, Bratislava, Slovakia., Ivanescu C; Patient Centered Solutions, IQVIA, Amsterdam, The Netherlands., Chin A; Analysis Group, Inc., Los Angeles, CA, USA., Betts KA; Analysis Group, Inc., Los Angeles, CA, USA., Lee CH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Choueiri TK; The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Cella D; Department of Medical Social Sciences, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. Electronic address: d-cella@northwestern.edu., Porta C; Interdisciplinary Department of Medicine, University of Bari 'A. Moro', Bari, Italy. Electronic address: camillo.porta@gmail.com.

Publikováno v: European urology oncology [Eur Urol Oncol] 2023 Jun; Vol. 6 (3), pp. 339-348. Date of Electronic Publication: 2023 Feb 25.